CIRSE

Over the last years, there has been a growing development and use of liquid embolic agents in IR, enabling the treatment of more complex diseases such as vascular trauma and bleeding, arteriovenous malformations, aneurysms, meningiomas, and subdural hematomas – conditions that otherwise could not be effectively treated with other embolic devices. Despite their increasing prevalence, these agents remain underused or unavailable in some hospitals, limiting treatment options for complex diseases. Liquid embolic agents represent an advancement over traditional mechanical embolic materials, making it crucial for interventional radiologists to be proficient in their use within clinical practice.The webinar will highlight key embolic agents such as sclerosants, Gelfoam, glue, and polymers, delving into their physical properties, indications, technical considerations, efficacy, and the latest innovations.Learning objectives:• To understand the differences between different types of liquid embolic agents and their specific uses.• To learn about the main liquid embolic devices currently in use and their composition.• To understand the clinical applications of liquid embolic devices during elective procedures.• To learn how to use embolic devices during emergency procedures.Programme:Introduction by the moderator - Alessandro Cannavale (Rome/IT)Clinical assessment of patients undergoing embolization procedures - Andreas Mahnken (Marburg/DE)Overview of currently available and upcoming embolic agents - Enrique Esteban Hernandez (Valencia/ES)Sclerosant agents and challenging cases - Lakshmi Ratnam (London/UK)Glue and LIPIODOL and challenging cases - Alberto Alonso-Burgos (Madrid/ES)Polymers and challenging cases - Romaric Loffroy (Dijon/FR)Discussion and Q&ATake home points by the moderator - Carolina Lanza (Milan/IT)FacultyModerators:• Alessandro Cannavale (Rome/IT)• Carolina Lanza (Milan/IT)Speakers:• Alberto Alonso-Burgos (Madrid/ES)• Enrique Esteban Hernandez (Valencia/ES)• Romaric Loffroy (Dijon/FR)• Andreas Mahnken (Marburg/DE)• Lakshmi Ratnam (London/GB)

Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a relatively new treatment method that uses drug-eluting microbeads to target tumours. It is essential for interventional radiologists to learn the indications, patient selection, procedural techniques, and the associated pros and cons of DEB-TACE treatment. Despite its well-known and proven clinical indication and efficacy, significant debate still persists regarding the most effective use of DEB-TACE, including its comparative efficacy to other techniques (cTACE, bland embolization), optimal embolic particle sizes, tumour staging considerations, potential complications, and overall therapeutic advantages. This webinar will provide participants with a thorough understanding of how to safely and effectively perform DEB-TACE for treating HCC and mCRC, along with insights into its evolving role in the future. During the case discussions, attendees will learn tips and tricks so that they can avoid potential complications and improve the treatment’s clinical value. Attendees will also have the opportunity to ask questions and engage in dynamic, interactive discussions based on real-world clinical experiences.Learning objectivesTo learn how to perform safe and effective DEB-TACE by real case examples.To understand patient selection on DEB-TACE for HCC and colorectal metastases.To understand the role of DEB-TACE in the current landscape of liver-directed locoregional therapies.ProgrammeIntroduction by the moderatorsRoberto Iezzi (Rome/IT) and Thomas Kröncke (Augsburg/DE)Role of DEB-TACE in HCCTobias Jakobs (Munich/DE)Role of DEB-TACE in mCRCGeert Maleux (Leuven/BE)Future of DEB-TACEThomas Helmsberger (Munich/DE)Discussion and Q&ATake-home points by the moderatorsRoberto Iezzi (Rome/IT) and Thomas Kröncke (Augsburg/DE)CME AccreditationThe CIRSE Webinar “DEB-TACE: Current standards in drug-eluting therapy for liver malignancies”, Vienna (ONLINE), Austria, 30/04/2025-30/04/2025 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.The accreditation is valid for the live event, as well as the on-demand content for a period of 6 months after the live webinar. Click here to learn more.Join free of charge!Access to this webinar is available free of charge to all interested parties. All you need is your CIRSE login details. Don’t have a CIRSE account yet? Not to worry! It only takes two minutes to set up a new account which will enable you to register.